ImmuPharma PLC Receives “Buy” Rating from Panmure Gordon (IMM)
ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating restated by equities research analysts at Panmure Gordon in a research note issued to investors on Thursday, Analyst Ratings Network reports. They currently have a GBX 150 ($2.38) price target on the stock. Panmure Gordon’s price objective indicates a potential upside of 118.18% from the stock’s previous close.
Shares of ImmuPharma PLC (LON:IMM) opened at 70.60 on Thursday. ImmuPharma PLC has a 52-week low of GBX 34.15 and a 52-week high of GBX 76.00. The stock’s 50-day moving average is GBX 49.0 and its 200-day moving average is GBX 42.99.
ImmuPharma plc is a drug discovery and development company. The Company focuses on developing drugs, based on peptide therapeutics, to treat medical conditions such as autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.